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Despite major advances in developing capacities and alternative technologies to egg-based production of 
influenza vaccines, responsiveness to an influenza pandemic threat is limited by the time it takes to generate a 
Candidate Viral Vaccine (CVV) as reported by the 2015 WHO Informal Consultation report titled “Influenza 
Vaccine Response during the Start of a Pandemic”. In previous work, we have shown that HEK-293 cell culture 
in suspension and serum free medium is an efficient production platform for cell culture manufacturing of 
influenza candidate vaccines. This report, took advantage of, recombinant DNA technology using Reverse 
Genetics of influenza A/Puerto Rico/8/34 H1N1 strain, and advances in the large-scale transfection of 
suspension cultured HEK-293 cells. Transfection in shake flasks was performed using 1ug of total plasmid and 
1x106 cells/mL. The supernatant was harvested after 48 hpt and used to infect a new shake flasks at 1x106 
cells/mL for virus amplification. 3-L bioreactor was inoculated and transfected at 1x106 cells/mL with 1ug of total 
plasmid and harvested after 48hpt and the virus generated was amplified in shake flask. Quantification by 
TCID50, SRID, Dot-blot and TRPS were performed as well as characterization by TEM and HA and NA 
sequencing. Small-scale transfection in shake flasks generated 1.5x105 IVP/mL after 48 hpt and 1x107 IVP/mL 
after 96 hpi. For large-scale experiment a 3-L controlled stirred tank bioreactor resulted in supernatant (P0) virus 
titer of 5x104 IVP/mL and 2.8x107 IVP/mL after only one amplification (P1) in HEK-293 suspension cells. We 
demonstrate the efficent generation of H1N1 with the PR8 backbone reassortant under controlled bioreactor 
conditions in two sequential steps (transfection/rescue and infection/production). This approach could deliver a 
CVV for influenza vaccine manufacturing within two-weeks, starting from HA and NA pandemic sequences. 
Thus, this innovative approach is better suited to rationally design and mass produce the CVV within timelines 
dictated by pandemic situations and produce effective responsiveness than previous methodology 
 
